Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy

by Nobuhiko Seki, Maika Natsume, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe
Published 2019-01-01

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

by Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe
Published 2019-01-01

Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review

by Shuji Ota, Takahiko Sakamoto, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Yuko Sasajima, Atsushi Mizota, Nobuhiko Seki
Published 2019-01-01

The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells

by Kazuhito Naka, Ryosuke Ochiai, Eriko Matsubara, Chie Kondo, Kyung-Min Yang, Takayuki Hoshii, Masatake Araki, Kimi Araki, Yusuke Sotomaru, Ko Sasaki, Kinuko Mitani, Dong-Wook Kim, Akira Ooshima, Seong-Jin Kim
Published 2020-09-01

Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis

by Shuji Ota, Yoshihide Fujigaki, Yoshifuru Tamura, Kenichiro Kojima, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki
Published 2019-01-01